News
2d
GlobalData on MSNSanofi’s Sarclisa gains EC approval for multiple myeloma treatmentThe European Commission (EC) has granted approval to Sanofi's Sarclisa in combination with a regimen of bortezomib, lenalidomide and dexamethasone (VRd) to treat multiple myeloma in adults. Sarclisa ...
Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma Approval based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd induction ...
Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma Approval based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd induction ...
Paris: Sanofi has announced that the European Commission has approved Sarclisa in combination with bortezomib, lenalidomide, ...
Following the positive opinion by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on ...
The European Commission has approved Sanofi’s Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) ...
Sanofi’s Sarclisa receives European approval to treat transplant-eligible newly diagnosed multiple myeloma: Paris Saturday, July 26, 2025, 09:00 Hrs [IST] Following the positive ...
Sanofi SA (EPA: SASY) announced Friday that its drug Sarclisa has received approval in the European Union for the treatment of transplant-eligible newly diagnosed ...
Sanofi is trumpeting new data for its anti-CD38 drug Sarclisa as it tries to capture market share from Johnson & Johnson’s blockbuster Darzalex in the multiple myeloma market.
Sanofi has agreed a deal with life sciences investor Blackstone to help fund clinical trials of a new formulation of Sarclisa for blood cancer multiple myeloma, accelerating its development ...
4don MSN
Vertiv (NYSE:VRT) has agreed to acquire the Great Lakes Data Racks & Cabinets family of companies for $200 million. Vicebio, ...
American depositary receipts of Adagene rose 15% in premarket trading following an investment from Sanofi. ADRs were trading around $2.24. The stock is down 2% on the year. Sanofi agreed to invest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results